Dual diagnosis of type 1 diabetes mellitus and attention deficit hyperactivity disorder.


Journal

Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345

Informations de publication

Date de publication:
06 2021
Historique:
revised: 25 09 2020
received: 24 07 2020
accepted: 07 02 2021
pubmed: 3 3 2021
medline: 27 1 2022
entrez: 2 3 2021
Statut: ppublish

Résumé

Data regarding glycemic control in children and adolescents with a dual diagnosis of type 1 diabetes mellitus (T1DM) and attention-deficit/hyperactivity disorder (ADHD) are limited. To compare various aspects of diabetes control among youth with T1DM, between those with and without ADHD. In this cross-sectional study of youth with T1DM, 39 had ADHD (mean age 14.1 ± 2.8 years) and 82 did not (control group, mean age 12.6 ± 3.3 years). Health-related quality of life was assessed by a Diabetes Quality of Life (DQOL) questionnaire submitted to their parents. Glycemic data were downloaded from glucometers, pumps, and continuous glucose monitoring systems. HbA1c levels, hospitalizations, and severe hypoglycemic and diabetes ketoacidosis events were retrieved from the medical files. Compared to the control group mean HbA1c level of the ADHD group was higher: 8.3 ± 1.1% versus 7.7 ± 1.0% (p = 0.005) and the percent of time that glucose level was in the target range (70-180 mg/dl) was lower: 48 ± 17% versus 59 ± 14% (p = 0.006). Mean glucose and glucose variability were higher in the ADHD group. Youth with ADHD who were not pharmacologically treated had worse HbA1c and more hospitalizations than those who were treated. DQOL did not differ between the control group, the treated ADHD group, and the untreated ADHD-Group. Dual diagnosis of T1DM and ADHD during childhood leads to worse diabetes control, which is more pronounced in the context of untreated ADHD. Healthcare providers should be aware of the difficulties facing youth with T1DM and ADHD in coping with the current intensive treatment of diabetes.

Sections du résumé

BACKGROUND
Data regarding glycemic control in children and adolescents with a dual diagnosis of type 1 diabetes mellitus (T1DM) and attention-deficit/hyperactivity disorder (ADHD) are limited.
OBJECTIVE
To compare various aspects of diabetes control among youth with T1DM, between those with and without ADHD.
METHODS
In this cross-sectional study of youth with T1DM, 39 had ADHD (mean age 14.1 ± 2.8 years) and 82 did not (control group, mean age 12.6 ± 3.3 years). Health-related quality of life was assessed by a Diabetes Quality of Life (DQOL) questionnaire submitted to their parents. Glycemic data were downloaded from glucometers, pumps, and continuous glucose monitoring systems. HbA1c levels, hospitalizations, and severe hypoglycemic and diabetes ketoacidosis events were retrieved from the medical files.
RESULTS
Compared to the control group mean HbA1c level of the ADHD group was higher: 8.3 ± 1.1% versus 7.7 ± 1.0% (p = 0.005) and the percent of time that glucose level was in the target range (70-180 mg/dl) was lower: 48 ± 17% versus 59 ± 14% (p = 0.006). Mean glucose and glucose variability were higher in the ADHD group. Youth with ADHD who were not pharmacologically treated had worse HbA1c and more hospitalizations than those who were treated. DQOL did not differ between the control group, the treated ADHD group, and the untreated ADHD-Group.
CONCLUSIONS
Dual diagnosis of T1DM and ADHD during childhood leads to worse diabetes control, which is more pronounced in the context of untreated ADHD. Healthcare providers should be aware of the difficulties facing youth with T1DM and ADHD in coping with the current intensive treatment of diabetes.

Identifiants

pubmed: 33651452
doi: 10.1111/pedi.13195
doi:

Substances chimiques

Blood Glucose 0
Hypoglycemic Agents 0
Insulin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

649-655

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007-1022.
Rader R, McCauley L, Callen EC. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder. Am Fam Physician. 2009;79(8):657-665.
Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol. 2010;25(3):157-173. https://doi.org/10.1093/arclin/acq014.
Curry AE, Yerys BE, Metzger KB, Carey ME, Power TJ. Traffic crashes, violations, and suspensions among young drivers with ADHD. Pediatrics. 2019;143(6):e20182305. https://doi.org/10.1542/peds.2018-2305.
Duke DC, Harris MA. Executive function, adherence, and glycemic control in adolescents with type 1 diabetes: a literature review. Curr Diab Rep. 2014;14(10):532. https://doi.org/10.1007/s11892-014-0532-y.
Osipoff JN, Dixon D, Wilson TA, Preston T. Prospective memory and glycemic control in children with type 1 diabetes mellitus: a cross-sectional study. Int J Pediatr Endocrinol. 2012;2012(1):29. https://doi.org/10.1186/1687-9856-2012-29.
McNally K, Rohan J, Pendley JS, Delamater A, Drotar D. Executive functioning, treatment adherence, and glycemic control in children with type 1 diabetes. Diabetes Care. 2010;33(6):1159-1162. https://doi.org/10.2337/dc09-2116.
Butwicka A, Frisén L, Almqvist C, Zethelius B, Lichtenstein P. Risks of psychiatric disorders and suicide attempts in children and adolescents with type 1 diabetes: a population-based cohort study. Diabetes Care. 2015;38(3):453-459. https://doi.org/10.2337/dc14-0262.
Kapellen TM, Reimann R, Kiess W, Kostev K. Prevalence of medically treated children with ADHD and type 1 diabetes in Germany-analysis of two representative databases. J Pediatr Endocrinol Metab. 2016;29(11):1293-1297. https://doi.org/10.1515/jpem-2016-0171.
Hilgard D, Konrad K, Meusers M, et al. Comorbidity of attention deficit hyperactivity disorder and type 1 diabetes in children and adolescents: analysis based on the multicentre DPV registry. Pediatr Diabetes. 2017;18(8):706-713. https://doi.org/10.1111/pedi.12431.
Lin S-Y, Lin C-L, Hsu W-H, Lin C-C, Fu Y-C. Association of attention deficit hyperactivity disorder with recurrent hypoglycemia in type 1 diabetes mellitus. Pediatr Diabetes. 2019;20(2):189-196. https://doi.org/10.1111/pedi.12716.
Nylander C, Lindström K, Khalifa N, Fernell E. Previously undiagnosed attention-deficit/hyperactivity disorder associated with poor metabolic control in adolescents with type 1 diabetes. Pediatr Diabetes. 2018;19(4):816-822. https://doi.org/10.1111/pedi.12651.
Vinker-Shuster M, Golan-Cohen A, Merhasin I, Merzon E. Attention-deficit hyperactivity disorder in pediatric patients with type 1 diabetes mellitus. J Dev Behav Pediatr. 2019;1:330-334. https://doi.org/10.1097/DBP.0000000000000670.
Yazar A, Akın F, Akça ÖF, et al. The effect of attention deficit/hyperactivity disorder and other psychiatric disorders on the treatment of pediatric diabetes mellitus. Pediatr Diabetes. 2019;20:345-352. https://doi.org/10.1111/pedi.12819.
Schiaffini R, Barbetti F, Rapini N, et al. School and pre-school children with type 1 diabetes during covid-19 quarantine: the synergic effect of parental care and technology. Diabetes Res Clin Pract. 2020;166:108302. https://doi.org/10.1016/j.diabres.2020.108302.
Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29(11):2433-2438. https://doi.org/10.2337/dc06-1085.
McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther. 2006;8(6):644-653. https://doi.org/10.1089/dia.2006.8.644.
Fritzsche G, Kohnert K-D, Heinke P, Vogt L, Salzsieder E. The use of a computer program to calculate the mean amplitude of glycemic excursions. Diabetes Technol Ther. 2011;13(3):319-325. https://doi.org/10.1089/dia.2010.0108.
Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631-1640. https://doi.org/10.2337/dc17-1600.
DuPaul GJ, Reid R, Anastopoulos AD, Lambert MC, Watkins MW, Power TJ. Parent and teacher ratings of attention-deficit/hyperactivity disorder symptoms: factor structure and normative data. Psychol Assess. 2016;28(2):214-225. https://doi.org/10.1037/pas0000166.
Berger I, Slobodin O, Cassuto H. Usefulness and validity of continuous performance tests in the diagnosis of attention-deficit hyperactivity disorder children. Arch Clin Neuropsychol. 2017;32(1):81-93. https://doi.org/10.1093/arclin/acw101.
Cohen-Cymberknoh M, Tanny T, Breuer O, et al. Attention deficit hyperactivity disorder symptoms in patients with cystic fibrosis. J Cyst Fibros. 2018;17(2):281-285. https://doi.org/10.1016/j.jcf.2017.11.020.
Skinner TC, Hoey H, McGee HM, Skovlund SE. Hvidøre study group on childhood diabetes. A short form of the diabetes quality of life for youth questionnaire: exploratory and confirmatory analysis in a sample of 2, 077 young people with type 1 diabetes mellitus. Diabetologia. 2006;49(4):621-628. https://doi.org/10.1007/s00125-005-0124-0.
Bennett JS. Quality of life in adolescents with type 1 diabetes. Int Diabetes Monit. 2007;19(2):30-32.
Frank E, Ozon C, Nair V, Othee K. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015;76(11):e1459. https://doi.org/10.4088/JCP.14r09478.
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. https://doi.org/10.2337/dci19-0028.
Lindblad I, Engström A-C, Nylander C, Fernell E. Adolescents with type 1 diabetes mellitus and attention-deficit/hyperactivity disorder require specific support from healthcare professionals. Acta Paediatr. 2017;106(12):1994-1997. https://doi.org/10.1111/apa.13989.
Coghill D, Hodgkins P. Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls. Eur Child Adolesc Psychiatry. 2016;25(3):261-271. https://doi.org/10.1007/s00787-015-0728-y.

Auteurs

Kineret Mazor-Aronovitch (K)

Pediatric Endocrinology and Diabetes Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Juvenile Diabetes Center, Maccabi Healthcare Services, Ra'anana, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Orit Pinhas-Hamiel (O)

Pediatric Endocrinology and Diabetes Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Juvenile Diabetes Center, Maccabi Healthcare Services, Ra'anana, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dikla Pivko-Levy (D)

The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Endocrinology and Diabetes Unit, Wolfson Medical Center, Holon, Israel.

Dalit Modan-Moses (D)

Pediatric Endocrinology and Diabetes Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Noa Levek (N)

Juvenile Diabetes Center, Maccabi Healthcare Services, Ra'anana, Israel.

Shahar Miller (S)

Department of Software and Information System Engineering, Ben-Gurion University of the Negev, Beersheba, Israel.

Michal Yackobovitch-Gavan (M)

Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Noah Gruber (N)

Pediatric Endocrinology and Diabetes Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Michal Ben-Ami (M)

Pediatric Endocrinology and Diabetes Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.

Eve Stern (E)

Pediatric Endocrinology and Diabetes Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.

Tal Ben-Ari (T)

The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Endocrinology and Diabetes Unit, Wolfson Medical Center, Holon, Israel.

Chana Graf-Barel (C)

Juvenile Diabetes Center, Maccabi Healthcare Services, Ra'anana, Israel.

Rachel Frumkin Ben-David (R)

Juvenile Diabetes Center, Maccabi Healthcare Services, Ra'anana, Israel.

Yael Levy-Shraga (Y)

Pediatric Endocrinology and Diabetes Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zohar Landau (Z)

Juvenile Diabetes Center, Maccabi Healthcare Services, Ra'anana, Israel.
Pediatric Division, Barzilai Medical Center, Ashkelon, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH